An observational study in Lower-risk Myelodysplastic Syndromes (TD LR-MDS), sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 5 of them phase 3. Myelodysplastic Syndromes · Bristol-Myers Squibb.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 3rd largest by planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2026, is one of 28 observational ones, and was the 74th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.
Browse Myelodysplastic Syndromes studies →4 of the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Germany
Ages 18+
Bristol-Myers Squibb · Sites in Singapore, Korea, Republic of, Taiwan
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Celgene · Sites in United States, Australia, Belgium and 19 more countries
Ages 18+
By country, each count listing its studies:
Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 20 · Phase 3 12 · Phase 4 1
First in 2001; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,300 is above the median of 150 across 214 observational studies indexed under Myelodysplastic Syndromes.
Median enrollment 56 across the 46 interventional studies, 200 across the 28 observational. Of the 63 that completed or were terminated, 20 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to understand the incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) and describing real-world first-line treatment patterns, healthcare resource utilization, and associated clinical outcomes in adult patients with TD LR-MDS in Spain
The study population will consist of adult participants diagnosed with transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS) identified in Spain using the BIG-PAC® database
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Overall cohort of participants with transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS)
Drug: Erythropoiesis-stimulating agents (ESAs) · Biological: Luspatercept · Drug: Lenalidomide · Drug: Hypomethylating agents (HMAs) · Biological: Reb blood cell transfusion
Participants that initiated first-line treatment with erythropoiesis-stimulating agents (ESAs)
Drug: Erythropoiesis-stimulating agents (ESAs)
Participants that initiated first-line treatment with luspatercept
Biological: Luspatercept
Participants that initiated first-line treatment with hypomethylating agents (HMAs)
Drug: Hypomethylating agents (HMAs)
Participants that initiated first-line treatment with lenalidomide
Drug: Lenalidomide
Participants that receive conservative management (red blood cell transfusions without disease modifying therapy)
Biological: Reb blood cell transfusion
Participants with low red-blood cell (RBC) transfusion dependance (\<4 RBC per 8 weeks)
Biological: Reb blood cell transfusion
Participants with moderate red-blood cell (RBC) transfusion dependance (4-5 RBC per 8 weeks)
Biological: Reb blood cell transfusion
Participants with high red-blood cell (RBC) transfusion dependance (≥6 RBC per 8 weeks)
Biological: Reb blood cell transfusion
Participants aged \<75 years
Drug: Erythropoiesis-stimulating agents (ESAs) · Biological: Luspatercept · Drug: Lenalidomide · Drug: Hypomethylating agents (HMAs) · Biological: Reb blood cell transfusion
Participants aged ≥75 years
Drug: Erythropoiesis-stimulating agents (ESAs) · Biological: Luspatercept · Drug: Lenalidomide · Drug: Hypomethylating agents (HMAs) · Biological: Reb blood cell transfusion
According to the product label
According to the product label
According to the product label
According to the product label
According to the product label
Incidence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS)
Time frame: Up to 5-years
Prevalence of transfusion dependent lower-risk myelodysplastic syndromes (TD LR-MDS)
Time frame: Up to 5-years
Proportion of participants receiving each first-line treatment category
Treatment categories include: * Erythropoiesis-stimulating agents (ESA) * Luspateracept * Hypomethylating agents (HMAs) * Lenalidomide * Conservative management (red-blood cell (RBC) transfusions without disease modifying therapy)
Time frame: Up to 5-years
Proportion of participants by treatment category at each line of therapy
Treatment category received at each line of therapy (first line, second line, third line and beyond), categorized as erythropoiesis-stimulating agents (ESA), luspatercept, hypomethylating agents (HMA), lenalidomide, or conservative management (red blood cell transfusions without disease-modifying therapy). Treatment sequences will be derived from retrospective medical chart abstraction of documented treatment start and stop dates.
Time frame: Up to 5-years
Treatment duration (time from initiation to discontinuation) of first-line treatment
Time frame: Up to 5-years
Defined as number of RBC units received per participant per 8-weeks
Time frame: Up to 5-years
Number and Rate of Healthcare Resource Utilization Events
Healthcare resource utilization events, including primary care visits, specialist visits, outpatient visits all-cause hospitalizations, transfusion-related hospitalizations, general laboratory tests, number of prescriptions related to transfusion-dependent lower-risk myelodysplastic syndromes, red blood cell transfusions, use of concomitant medicines related to other comorbidities as documented in participant medical records.
Time frame: Up to 5-years
Number of participants that achieve hematologic improvement-erythroid (HI-E)
Time frame: Up to 5-years
Number of participants that achieve red-blood cell (RBC) transfusion independence (TI)
Time frame: Up to 5-years
Number of participants that experience a change in transfusion burden (change in number of red-blood cell units received per 8-weeks)
Time frame: Up to 5-years
Number of participants that progress to higher-risk myelodysplastic syndromes (MDS)
Time frame: Up to 5-years
Number of participants that progress to acute myeloid leukemia (AML)
Time frame: Up to 5-years
Number of participants that do not respond to first-line treatment
Time frame: Up to 5-years
Number of participants that experience loss of response/secondary failure after an initial hematologic response
Time frame: Up to 5-years
Cause of death
Time frame: Up to 5-years
Serious adverse events (SAEs)
Time frame: Up to 5-years
Number of serious cardiovascular events requiring emergency room visit or hospitalization
Cardiovascular events include: will include acute myocardial infarction or acute coronary syndrome, heart failure decompensation, clinically significant arrhythmias (including atrial fibrillation/flutter and ventricular arrhythmia), stroke or transient ischemic attack, and venous thromboembolism.
Time frame: Up to 5-years
Participant age
Time frame: Baseline
Participant sex
Time frame: Baseline
Year of first-line treatment initiation
Time frame: Baseline
Participant Body mass index (BMI)
Time frame: Baseline
Participant Charlson Comorbidity Index (CCI) score
Time frame: Baseline
Participant Charlson Comorbidity Index (CCI) individual comorbidities
Time frame: Baseline
Number of comorbidities
Time frame: Baseline
Smoking status
Time frame: Baseline
Plan to share: No
Ran from Feb 2026 to primary completion in Apr 2026, 2 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Mar 2026 → Apr 2026 and completion May 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.